HLB Life Science Co

HLB Life Science Co EBIT

The EBIT of HLB Life Science Co (067630.KQ) as of Oct 17, 2026 is -21.02 B KRW. In the previous year, EBIT was 18.13 B KRW — a change of -215.98% (lower).

EBIT

-21.02 BKRW

YoY

-215.98%

Last updated:

In 2025, HLB Life Science Co's EBIT was -21.02 B KRW, a -215.98% increase from the 18.13 B KRW EBIT recorded in the previous year.

The HLB Life Science Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2017
1.79 B KRW
Jan 1, 2018
-7.96 B KRW
Jan 1, 2019
-37.61 B KRW
Jan 1, 2020
-8.02 B KRW
Jan 1, 2021
-18.33 B KRW
Jan 1, 2023
-65.51 B KRW
Jan 1, 2024
18.13 B KRW
Jan 1, 2025
-21.02 B KRW
The HLB Life Science Co EBIT history
YEAREBITYoY
-21.02 BKRW-215.98%
18.13 BKRW-127.67%
-65.51 BKRW+257.41%
-18.33 BKRW+128.60%
-8.02 BKRW-78.68%
-37.61 BKRW+372.25%
-7.96 BKRW-544.37%
1.79 BKRW-226.93%
-1.41 BKRW-90.02%
-14.15 BKRW-1,074.69%
1.45 BKRW-166.34%
-2.19 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HLB Life Science Co Revenue

HLB Life Science Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
102.48 B KRW
-7.96 B KRW
-3.07 B KRW
Jan 1, 2019
114.02 B KRW
-37.61 B KRW
-7.60 B KRW
Jan 1, 2020
91.80 B KRW
-8.02 B KRW
-55.80 B KRW
Jan 1, 2021
53.49 B KRW
-18.33 B KRW
-49.15 B KRW
Jan 1, 2022
99.59 B KRW
0.00 KRW
-54.28 B KRW
Jan 1, 2023
97.99 B KRW
-65.51 B KRW
-5.98 B KRW
Jan 1, 2024
102.24 B KRW
18.13 B KRW
6.14 B KRW
Jan 1, 2025
45.75 B KRW
-21.02 B KRW
-99.79 B KRW

HLB Life Science Co Margins

HLB Life Science Co stock margins

The HLB Life Science Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of HLB Life Science Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for HLB Life Science Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
4.56 %
-7.77 %
-2.99 %
Jan 1, 2019
6.67 %
-32.98 %
-6.67 %
Jan 1, 2020
4.99 %
-8.73 %
-60.78 %
Jan 1, 2021
-5.71 %
-34.26 %
-91.88 %
Jan 1, 2022
-3.06 %
0.00 %
-54.50 %
Jan 1, 2023
-0.76 %
-66.85 %
-6.11 %
Jan 1, 2024
-2.14 %
17.73 %
6.00 %
Jan 1, 2025
-1.08 %
-45.95 %
-218.12 %

HLB Life Science Co Stock analysis

What does HLB Life Science Co do? HLB Life Science Co., Ltd. is a leading company in the research, development, and production of biotechnological and pharmaceutical products. The company was founded in 2015 in Seoul, South Korea. Due to the founders' extensive experience in the field of life science and biotechnology, HLB Life Science has quickly established itself as a key player in the industry. HLB Life Science's business model is based on the development and production of innovative biotechnological and pharmaceutical products, as well as collaboration with other companies and research institutions. The aim is to improve people's quality of life by providing effective and safe medications and therapies. The company is divided into various divisions. The Biopharmaceuticals division includes the development and production of biotechnological products such as antibodies, proteins, vaccines, and diagnostics. The Pharmaceuticals division develops and produces advanced drugs in the field of oncology, immunology, and neurology. The Clinical Research Services division offers contract research services in the field of clinical studies to test the effectiveness and safety of drugs. In addition, HLB Life Science Co., Ltd. is also active in the Nutra-Pharmaceuticals division, specializing in the development and production of dietary supplements. HLB Life Science offers various products tailored to the needs of patients. In the field of Biopharmaceuticals, for example, the company produces antibodies and proteins for the treatment of cancer, inflammatory diseases, and infections. Another innovative product is a fully humanized antibody against the hepatitis B virus, which is one of the most common liver diseases. In the Pharmaceuticals field, HLB Life Science offers innovative drugs for the treatment of cancer, autoimmune diseases, and neurological disorders. In the Nutra-Pharmaceuticals field, the company offers dietary supplements based on natural ingredients that can strengthen the immune system. HLB Life Science Co., Ltd. is known in the industry for its innovative strength and excellent research results. The company places great emphasis on continuous research and development to develop innovative products and continuously improve existing products. Due to their outstanding products and services, HLB Life Science has already exported to various countries worldwide and has thus played a significant role in the global market. Looking to the future, HLB Life Science Co., Ltd. continues to focus on innovative research and development, as well as close collaboration with universities and research institutions. The company aims to improve people's health and well-being through effective and safe medications and therapies. HLB Life Science Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing HLB Life Science Co's EBIT

HLB Life Science Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of HLB Life Science Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

HLB Life Science Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in HLB Life Science Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about HLB Life Science Co stock

EBIT of HLB Life Science Co is -21.02 B KRW in 2025.

EBIT of HLB Life Science Co changed from 18.13 B KRW to -21.02 B KRW, representing a -215.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT HLB Life Science Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's HLB Life Science Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — HLB Life Science Co

All Key Metrics — HLB Life Science Co